{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": null, "document_type": "article", "multimedia": [], "abstract": "Supreme Court rules that Teva Pharmaceutical Industries could continue to benefit from patent protection from its multiple sclerosis drug Copaxone, sending case back to federal appeals court for revaluation; decision deals blow to generic competitors.", "type_of_material": "News", "word_count": "387", "lead_paragraph": "The court said the company could still benefit from patent protection for the multiple sclerosis drug, dealing a blow to makers of generic drugs.", "pub_date": "2015-01-21T00:00:00Z", "_id": "54beb66c38f0d826e07c1104", "byline": {"contributor": "", "original": "By REUTERS", "person": [], "organization": "REUTERS"}, "source": "The New York Times", "snippet": "The court said the company could still benefit from patent protection for the multiple sclerosis drug, dealing a blow to makers of generic drugs.", "web_url": "http://www.nytimes.com/2015/01/21/business/supreme-court-rules-in-favor-of-teva-in-copaxone-patent.html", "slideshow_credits": null, "blog": [], "keywords": [{"rank": "1", "is_major": "Y", "value": "Teva Pharmaceutical Industries Ltd", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Supreme Court (US)", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Multiple Sclerosis", "name": "subject"}, {"rank": "5", "is_major": "Y", "value": "Inventions and Patents", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Israel", "name": "glocations"}], "headline": {"main": "Supreme Court Rules in Favor of Teva Over Patent for Multiple Sclerosis Drug", "print_headline": "Supreme Court Rules for Teva on Multiple Sclerosis Patent"}}